? Cancer Center Administration Abramson Cancer Center (ACC) Administration is responsible for supporting the ACC, an internationally renowned, NCI-Designated Comprehensive Cancer Center, in the management of resources and services required to facilitate the scientific mission of reducing the burden of cancer. These activities include strategic planning, evaluation, and decision-making; governance and management of the fiscal and administrative components of multiple ACC- and Cancer Center Support Grant (CCSG)-related activities; and management of Shared Resources, membership, the CCSG application, research and grant administration, and events and communication. Administration coordinates with other ACC activities (Community Outreach and Engagement, and Cancer Research Training and Education Coordination) as well as other support offices in the ACC, such as: Clinical Protocol and Data Management (CPDM)'s Department of Operations, Compliance and Monitoring; Development; and the Office of Legal Affairs. It represents the Center within the parent Institution and to the NCI and other external entities. The challenge of executing these priorities in a complex matrix cancer center requires Administration to have the talent, experience, and expertise necessary to support multiple constituent priorities (both internal and external), while maintaining dedication to their mission. ACC Administration comprises a cohesive group of highly experienced staff with the demonstrated proficiency necessary to skillfully meet the needs of ACC members, who accomplished unprecedented growth and success in the past decade. These key administrative staff members have clearly defined roles and responsibilities, with appropriate reporting lines both internally and within the larger Penn Medicine institution, to ensure that the administrative activities of the ACC are delivered in an effective and efficient manner.
Specific aims are to: 1) Administratively lead in the governance and decision-making processes of the ACC; 2) Deliver efficient and effective professional administrative oversight, financial management, and non-administrative and regulatory guidance to support cancer research activities, including all activities specifically related to the CCSG; and 3) Represent the interests of the ACC both within the parent Institution and with external groups, to ensure the Center adheres to, and helps shape, policies that govern its activities.
|Nicastri, Michael C; Rebecca, Vito W; Amaravadi, Ravi K et al. (2018) Dimeric quinacrines as chemical tools to identify PPT1, a new regulator of autophagy in cancer cells. Mol Cell Oncol 5:e1395504|
|Micallef, Ivana N; Stiff, Patrick J; Nademanee, Auayporn P et al. (2018) Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report. Biol Blood Marrow Transplant 24:1187-1195|
|Medvec, Andrew R; Ecker, Christopher; Kong, Hong et al. (2018) Improved Expansion and In Vivo Function of Patient T Cells by a Serum-free Medium. Mol Ther Methods Clin Dev 8:65-74|
|Acosta, Jonuelle; Wang, Walter; Feldser, David M (2018) Off and back-on again: a tumor suppressor's tale. Oncogene 37:3058-3069|
|Crisalli, Lisa M; Hinkle, Joanne T; Walling, Christopher C et al. (2018) Higher Donor Apheresis Blood Volumes Are Associated with Reduced Relapse Risk and Improved Survival in Reduced-Intensity Allogeneic Transplantations with Unrelated Donors. Biol Blood Marrow Transplant 24:1203-1208|
|Mazaleuskaya, Liudmila L; Salamatipour, Ashkan; Sarantopoulou, Dimitra et al. (2018) Analysis of HETEs in human whole blood by chiral UHPLC-ECAPCI/HRMS. J Lipid Res 59:564-575|
|Facompre, Nicole D; Harmeyer, Kayla M; Sahu, Varun et al. (2018) Targeting JARID1B's demethylase activity blocks a subset of its functions in oral cancer. Oncotarget 9:8985-8998|
|Rosenfeld, Aaron M; Meng, Wenzhao; Chen, Dora Y et al. (2018) Computational Evaluation of B-Cell Clone Sizes in Bulk Populations. Front Immunol 9:1472|
|Shroff, Rachna T; Hendifar, Andrew; McWilliams, Robert R et al. (2018) Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation. JCO Precis Oncol 2018:|
|Fraietta, Joseph A; Lacey, Simon F; Orlando, Elena J et al. (2018) Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med 24:563-571|
Showing the most recent 10 out of 1047 publications